Search Results - "Galambos, Michael R"

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis by Bowlus, Christopher L, Galambos, Michael R, Aspinall, Richard J, Hirschfield, Gideon M, Jones, David E J, Dörffel, Yvonne, Gordon, Stuart C, Harrison, Stephen A, Kremer, Andreas E, Mayo, Marlyn J, Thuluvath, Paul J, Levy, Cynthia, Swain, Mark G, Neff, Guy W, Sheridan, David A, Stanca, Carmen M, Berg, Christoph P, Goel, Aparna, Shiffman, Mitchell L, Vierling, John M, Boudes, Pol, Steinberg, Alexandra, Choi, Yun-Jung, McWherter, Charles A

“…We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary…”
Get full text

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis by Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., Dörffel, Yvonne, Yang, Ke, Choi, Yun‐Jung, McWherter, Charles A.

“…Summary Background Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in…”
Get full text

Are Colonoscopies Performed in Private Offices Less Likely to Be Successful? by Rubin, Raymond A., MD, AGAF, Galambos, Michael R., MD

Get full text

Featured Cover by Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., Dörffel, Yvonne, Yang, Ke, Choi, Yun‐Jung, McWherter, Charles A.

“…The cover image is based on the Fast Track Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary…”
Get full text

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study by Jones, David, Boudes, Pol F, Swain, Mark G, Bowlus, Christopher L, Galambos, Michael R, Bacon, Bruce R, Doerffel, Yvonne, Gitlin, Norman, Gordon, Stuart C, Odin, Joseph A, Sheridan, David, Wörns, Markus-Alexander, Clark, Virginia, Corless, Linsey, Hartmann, Heinz, Jonas, Mark E, Kremer, Andreas E, Mells, George F, Buggisch, Peter, Freilich, Bradley L, Levy, Cynthia, Vierling, John M, Bernstein, David E, Hartleb, Marek, Janczewska, Ewa, Rochling, Fedja, Shah, Hemant, Shiffman, Mitchell L, Smith, John H, Choi, Yun-Jung, Steinberg, Alexandra, Varga, Monika, Chera, Harinder, Martin, Robert, McWherter, Charles A, Hirschfield, Gideon M

“…Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective…”
Get more information

Noncirrhotic Portal Hypertension in Patients With Human Immunodeficiency Virus–1 Infection by Saifee, Sophia, Joelson, Dean, Braude, James, Shrestha, Roshan, Johnson, Mark, Sellers, Marty, Galambos, Michael R, Rubin, Raymond A

“…Background & Aims Noncirrhotic portal hypertension (NCPH) is unusual in North American patients. This study characterized patients with NCPH and human…”
Get full text

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study by Hirschfield, Gideon M, Shiffman, Mitchell L, Gulamhusein, Aliya, Kowdley, Kris V, Vierling, John M, Levy, Cynthia, Kremer, Andreas E, Zigmond, Ehud, Andreone, Pietro, Gordon, Stuart C, Bowlus, Christopher L, Lawitz, Eric J, Aspinall, Richard J, Pratt, Daniel S, Raikhelson, Karina, Gonzalez-Huezo, Maria S, Heneghan, Michael A, Jeong, Sook-Hyang, Ladrón de Guevara, Alma L, Mayo, Marlyn J, Dalekos, George N, Drenth, Joost P H, Janczewska, Ewa, Leggett, Barbara A, Nevens, Frederik, Vargas, Victor, Zuckerman, Eli, Corpechot, Christophe, Fassio, Eduardo, Hinrichsen, Holger, Invernizzi, Pietro, Trivedi, Palak J, Forman, Lisa, Jones, David E J, Ryder, Stephen D, Swain, Mark G, Steinberg, Alexandra, Boudes, Pol F, Choi, Yun-Jung, McWherter, Charles A

“…ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus…”
Get full text

A radioimmunoassay procedure for type III procollagen: its use in the detection of hepatic fibrosis by Galambos, M R, Collins, D C, Galambos, J T

“…Recent studies suggest that the serum level of Type III procollagen (PC-III) could be a valuable, noninvasive monitor of hepatic fibrogenesis. We have…”
Get more information